Evidence map›Paper›PMID 37942320›Full record

ArticleFrontiers in immunology2023

Dexamethasone impairs the expression of antimicrobial mediators in lipopolysaccharide-activated primary macrophages by inhibiting both expression and function of interferon β.

John D O'Neil, Oliwia O Bolimowska, Sally A Clayton, Tina Tang, Kalbinder K Daley, Samuel Lara-Reyna, Jordan Warner, Claire S Martin, Rahul Y Mahida, Rowan S Hardy and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

John D O'Neil *Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.
Oliwia O Bolimowska *Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.
Sally A Clayton *Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.
Tina TangInstitute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.
Kalbinder K DaleyInstitute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.
Samuel Lara-ReynaInstitute of Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom.
Jordan WarnerSchool of Life Sciences, University of Dundee, Dundee, United Kingdom.
Claire S MartinSchool of Biomedical Sciences, University of Birmingham, Birmingham, United Kingdom.
Rahul Y MahidaInstitute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.
Rowan S HardySchool of Biomedical Sciences, University of Birmingham, Birmingham, United Kingdom.
J Simon C ArthurSchool of Life Sciences, University of Dundee, Dundee, United Kingdom.
Andrew R ClarkInstitute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.
University of Birmingham · GBUniversity of Dundee · GB

Funding

Medical Research Council MR/N021185/1Medical Research Council MR/X000338/1Versus Arthritis 21802Versus Arthritis 22072
6 · The paper itself

Abstract

Glucocorticoids potently inhibit expression of many inflammatory mediators, and have been widely used to treat both acute and chronic inflammatory diseases for more than seventy years. However, they can have several unwanted effects, amongst which immunosuppression is one of the most common. Here we used microarrays and proteomic approaches to characterise the effect of dexamethasone (a synthetic glucocorticoid) on the responses of primary mouse macrophages to a potent pro-inflammatory agonist, lipopolysaccharide (LPS). Gene ontology analysis revealed that dexamethasone strongly impaired the lipopolysaccharide-induced antimicrobial response, which is thought to be driven by an autocrine feedback loop involving the type I interferon IFNβ. Indeed, dexamethasone strongly and dose-dependently inhibited the expression of IFNβ by LPS-activated macrophages. Unbiased proteomic data also revealed an inhibitory effect of dexamethasone on the IFNβ-dependent program of gene expression, with strong down-regulation of several interferon-induced antimicrobial factors. Surprisingly, dexamethasone also inhibited the expression of several antimicrobial genes in response to direct stimulation of macrophages with IFNβ. We tested a number of hypotheses based on previous publications, but found that no single mechanism could account for more than a small fraction of the broad suppressive impact of dexamethasone on macrophage type I interferon signaling, underlining the complexity of this pathway. Preliminary experiments indicated that dexamethasone exerted similar inhibitory effects on primary human monocyte-derived or alveolar macrophages.

Indexed as

Anti-Infective AgentsLipopolysaccharidesAnimalsDexamethasoneGlucocorticoidsHumansInterferon-betaMacrophagesMiceProteomicsAnti-Infective AgentsDexamethasoneGlucocorticoidsInterferon-betaLipopolysaccharidesdexamethasoneglucocorticoidinnate immunityinterferon βmacrophageSARS-CoV-2type I interferonvirus

Identifiers

PMID37942320
PMCPMC10628473
OpenAlexW4387899097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.